NAS10026,944+1.18%S&P7,385+0.42%GOLD$4,067−1.12%BTC$75,586−0.47%VIX25.28−10.29%latest tape · as of 18:01 UTC
The Screen · Healthcare · Drug Manufacturers - Specialty & Generic
Elanco Animal Health Inc
ELAN · the NYSE · USD · Market cap $11.3B · 9,400 employees
Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals worldwide.
Positioning no disclosures inside 60 days, left as found
Options put/call open interest 0.23, read 2026-11-05
Ethical passes the values gate
Price23.68 USD
Fair value24.74
Ethical score70.0/100
Value readFairas of 5 Nov 2026
Our investment reviews on this name
2026-10-21Read Accumulation23.54+0.6% to today ✓Markdown gives way to Accumulation while volume is distributing
2026-10-02Read Markdown22.43+5.6% to today Distribution gives way to Markdown with volume flow in agreement
2026-08-27Read Distribution22.51+5.2% to today Markup gives way to Distribution after a 7% slide in 8 weeks
2026-07-02Read Markup24.17-2.0% to today First review on file: Markup
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
Elanco Animal Health Inc holds its Accumulation at $23.68. The statistical read favours the sellers, held for 39 days.
As held on the ledger · 2026-11-05
Phase
Accumulation
Quantitative state
The statistical read favours the sellers, held for 39 days
Price at the screen
$23.68
Valuation
N/A trailing · 17.51 forward price to earnings
Values screen
PASS· score 70.0
Beta
1.71
The Workings
Five Screens, Shown in Full
Full pass across all five screens. This security clears the Titan Ethical Standard: its business and its balance sheet both stay inside the lines.
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
30.07%
Below 33%
Interest-bearing debt is just 30.1% of its assets, well under the one-third ceiling: it does not run on borrowed money.
Pass
Interest-bearing cash
0.00%
Below 33%
Cash held in interest-bearing accounts and securities is 0.0% of assets, under the one-third limit.
Pass
Receivables
10.62%
Below 49%
Money owed to the company is 10.6% of assets, under the 49% limit.
Pass
Revenue purity
0.91%
Below 5%
Only 0.9% of revenue comes from non-compliant sources, under the 5% line.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
Why It Clears, in Plain English
Elanco Animal Health clears all five screens. Its business is in a permissible area, its interest-bearing debt is about 30%, inside the ~33% line, and almost none of its income is interest, so it passes.
Read as at 2026-11-05. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when ELAN's ethical verdict changes
Today ELAN passes the screen. If new figures move it to a fail, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
What the Numbers Say It Is Worth
The Fair Value Range
Our analysis reads Fair vs our fair value, as of 5 Nov 2026: it trades above our $24.74 fair value estimate, narrow competitive moat, 10.20% revenue growth.
Fair value range in USD, drawn from the 2026-11-05 screen. The gold marker is the market price at the same screen. A 4.3% discount to the base estimate.
Third-party analyst targets: 13 covering, consensus Buy. The average target sits +27% from the screen price.
Reading the gap · Our more conservative model reads it as roughly fairly valued here, while the Street is more bullish: a quality-at-a-fair-price name rather than a deep-value one.
Where our models see it going: fair-value estimate $24.74, with a range of $21.60 to $28.45, dated to the 2026-11-05 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Farm Animals and Pets Drive Steady Revenue
Every time a dairy herd gets vaccinated or a spaniel is treated for fleas, the bill lands with companies like Elanco. Revenue is rising 15 percent, yet the firm still posts a 5 percent loss and negative 4 percent return on equity. A narrow moat and 21.6 times forward earnings leave almost no margin of safety at the current price.
The business clears our ethical screen and analysts see upside to 30 dollars, but our fair value sits only a percent above the market price. That slim gap, combined with ongoing losses, produces an opportunity rating of none.
Animal health can swing with farm incomes and pet spending cycles. One bad season or a competitor launch could widen the losses further. Analysis, not advice.
Another profit measure, before interest, tax and non-cash costs: EBITDA.
The risks · The things to watch: it already moves more than the market on an average day; as a drug manufacturers - specialty & generic name, trial and regulatory outcomes can move it sharply either way.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
ELAN trades on the NYSE. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-11-06Accumulation$23.68-6.4%Entry 17
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 6.4% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are up 60%. Our forward projection puts the odds of a 10% gain over the next month near 29%. The street (14 analysts) rates it strong buy, with a mean price target of $30. It reported earnings in this window, a natural checkpoint for the thesis.
2026-11-05Accumulation$25.31+3.0%Entry 16
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 3.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are up 60%. Our forward projection puts the odds of a 10% gain over the next month near 29%. The street (14 analysts) rates it strong buy, with a mean price target of $30. It reported earnings in this window, a natural checkpoint for the thesis.
2026-11-04Accumulation$24.57+2.0%Entry 15
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 2.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are up 60%. Our forward projection puts the odds of a 10% gain over the next month near 29%. The street (14 analysts) rates it strong buy, with a mean price target of $30. It reported earnings in this window, a natural checkpoint for the thesis.
2026-11-03Accumulation$24.10+4.5%Entry 14
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 4.5% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are up 60%. Our forward projection puts the odds of a 10% gain over the next month near 29%. The street (14 analysts) rates it strong buy, with a mean price target of $30. It reported earnings in this window, a natural checkpoint for the thesis.
2026-11-02Accumulation$23.06+0.0%Entry 13
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are up 60%. Our forward projection puts the odds of a 10% gain over the next month near 29%. The street (14 analysts) rates it strong buy, with a mean price target of $30. It reported earnings in this window, a natural checkpoint for the thesis.
2026-11-01Accumulation$23.06+0.0%Entry 12
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are up 60%. Our forward projection puts the odds of a 10% gain over the next month near 29%. The street (14 analysts) rates it strong buy, with a mean price target of $30. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-31Accumulation$23.06-0.8%Entry 11
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.8% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are up 60%. Our forward projection puts the odds of a 10% gain over the next month near 29%. The street (14 analysts) rates it strong buy, with a mean price target of $30. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-30Accumulation$23.24+3.2%Entry 10
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 3.2% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are up 60%. Our forward projection puts the odds of a 10% gain over the next month near 29%. The street (14 analysts) rates it strong buy, with a mean price target of $30. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-28Accumulation$22.52-4.3%Entry 9
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 4.3% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are up 60%. Our forward projection puts the odds of a 10% gain over the next month near 29%. The street (14 analysts) rates it strong buy, with a mean price target of $30.
The framework has shifted from markdown to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 2.7% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is momentum reading bullish. Over the past year the shares are up 60%. Our forward projection puts the odds of a 10% gain over the next month near 29%. The street (14 analysts) rates it strong buy, with a mean price target of $30.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
